RBCC Partner n3D’s Latest Article Shows Magnetic Bioprinting’s Versatility and Promise

partner n3D has gotten a key article published on a recognized medical
technology company’s website, giving n3D and its considerable
bioprinting expertise greater marketplace recognition and valuable

Promega, a life sciences company offering genomics, cellular analysis,
drug discovery and genetic identity products and solutions, issued n3D’s
paper, entitled, Luminescent
Viability Assays in Magnetically Bioprinting 3D Cultures
on its PubHub
page, which offers ground-breaking articles on new technologies.

n3D’s publication demonstrates “a magnetic 3D bioprinting method for
rapidly and reproducibly printing three-dimensional spheroids in
high-throughput formats.” The paper proceeds to show how these spheroids
can be successfully used in critical cell viability tests utilizing a
number of specific products.

“The paper shows magnetic bioprinting’s tremendous utility and value in
the life sciences field,” Souza said. “It is particularly useful in
compound screening, as we discussed in the article. We continue to make
rapid and substantial advancements using this cutting-edge technology
that will soon lead to new drugs and treatments to many diseases. n3D’s
bioprinting technologies have a distinct edge as they offer researchers
simplicity of use when working with delicate tissues and cells. Magnetic
bioprinting has strong research and commercial applications and we
predict great market potential ahead.”

RBCC CEO Kimberly Palmer added, “n3D has made great strides in magnetic
bioprinting and this is the only commercially viable 3D bioprinting
process on the market. We believe this revolutionary technology will
truly change medicine and we’re proud to have stood beside them through
this development process.”

For more information on RBCC’s initiatives, please visit www.rainbowbiosciences.com.

About Rainbow Biosciences

Biosciences, LLC
, is a wholly owned subsidiary of Rainbow Coral
Corp. (RBCC).
The Company continually seeks out new partnerships with biotechnology
developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business
initiatives, please visit www.RainbowBioSciences.com.
For investment information and performance data on the Company, please
visit www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform
Act of 1995: This news release contains forward-looking information
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, including statements that include the words “believes,”
“expects,” “anticipate” or similar expressions. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results, performance or achievements
of the Company to differ materially from those expressed or implied by
such forward-looking statements. In addition, description of anyone’s
past success, either financial or strategic, is no guarantee of future
success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information
included herein for events occurring after the date hereof.


Rainbow Coral Corp.
Kimberly Palmer, 702-940-2345
and CEO